These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14569515)

  • 1. [Chemoprevention of breast cancer: a literature review and report on the current status in Germany].
    Paepke S; V Minckwitz G; Kaufmann M; Schwarz-Boeger U; Jacobs VR; Aigner M; Pfeifer K; Ehmer M; Hüttner C; Blohmer JU; Kiechle M
    Zentralbl Gynakol; 2003 Sep; 125(9):338-45. PubMed ID: 14569515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Breakthrough in breast cancer chemoprevention].
    Kahán Z; Thurzó L
    Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
    Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
    Loehberg CR; Jud SM; Haeberle L; Heusinger K; Dilbat G; Hein A; Rauh C; Dall P; Rix N; Heinrich S; Buchholz S; Lex B; Reichler B; Adamietz B; Schulz-Wendtland R; Beckmann MW; Fasching PA
    Breast Cancer Res Treat; 2010 May; 121(1):101-10. PubMed ID: 20306293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of breast cancer.
    Castrellon AB; Glück S
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].
    Ricart JJ
    Medicina (B Aires); 2004; 64(1):66-72. PubMed ID: 15034961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of breast cancer chemoprevention.
    Chang JC
    Biomed Pharmacother; 1998; 52(3):133-6. PubMed ID: 9755806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
    Dunn BK; Ryan A
    Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SERMs in chemoprevention of breast cancer.
    Gasco M; Argusti A; Bonanni B; Decensi A
    Eur J Cancer; 2005 Sep; 41(13):1980-9. PubMed ID: 15964182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs.
    Fasching PA; von Minckwitz G; Fischer T; Kaufmann M; Schultz-Zehden B; Beck H; Lux MP; Jacobs V; Meden H; Kiechle M; Beckmann MW; Paepke S
    Breast Cancer Res Treat; 2007 Jan; 101(1):95-104. PubMed ID: 17033928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.
    Paterniti DA; Melnikow J; Nuovo J; Henderson S; DeGregorio M; Kuppermann M; Nease R
    Ethn Dis; 2005; 15(3):365-72. PubMed ID: 16108294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
    Kendall A; Dowsett M
    Endocr Relat Cancer; 2006 Sep; 13(3):827-37. PubMed ID: 16954432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of hormone-related cancers: breast cancer.
    Dunn BK; Wickerham DL; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
    Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer risk in primary care: implications for chemoprevention.
    Lewis CL; Kinsinger LS; Harris RP; Schwartz RJ
    Arch Intern Med; 2004 Sep; 164(17):1897-903. PubMed ID: 15451765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.